Showing results (111-120 of 131) with videos related to

Sort By:
Pageof 14
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 27, 2013
Clinical relevance of cancer stem cells in bone marrow of early breast cancer patientsA Giordano, H Gao, E N Cohen, et al.
Molecular Cancer Therapeutics|December 19, 2006
Bisphenol A facilitates bypass of androgen ablation therapy in prostate cancerYelena B Wetherill, Janet K Hess-Wilson, Clay E S Comstock, et al.
International Journal of Obesity (2005)|November 3, 2010
Neprilysin, obesity and the metabolic syndromeK F Standeven, K Hess, A M Carter, et al.
Frontiers in Genetics|June 28, 2024
Puberty classifications in beef heifers are moderately to highly heritable and associated with candidate genes related to cyclicity and timing of pubertyMelanie K Hess, Anteneh Mersha, Sadie S Ference, et al.
Diabetologia|September 16, 2011
A novel mechanism for hypofibrinolysis in diabetes: the role of complement C3K Hess, S H Alzahrani, M Mathai, et al.
Journal of Neurosurgery|January 10, 2002
A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survivalM Lacroix, D Abi-Said, D R Fourney, et al.
The Journal of Clinical Endocrinology and Metabolism|March 2, 2012
Thyroid dysfunction and fibrin network structure: a mechanism for increased thrombotic risk in hyperthyroid individualsJ M W Hooper, D J F Stuijver, S M Orme, et al.
Archives of Dermatological Research|April 22, 2016
Merkel cell polyomavirus and human papilloma virus in proliferative skin lesions arising in patients treated with BRAF inhibitorsG S Falchook, P Rady, J C Konopinski, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 12, 2004
Gene expression profiles predict complete pathologic response to neoadjuvant paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide chemotherapy in breast cancerM Ayers, W F Symmans, J Stec, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 12, 2015
Phase I study of pazopanib and vorinostat: a therapeutic approach for inhibiting mutant p53-mediated angiogenesis and facilitating mutant p53 degradationS Fu, M M Hou, A Naing, et al.
Pageof 14